LONDON and RALEIGH, N.C., April 10, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc VRNA (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its development partner, Nuance Pharma, has dosed the first subject in its ENHANCE – China Phase 3 trial for the maintenance treatment…Read More
Nuance Pharma Announces Dosing of First Patient in ENHANCE China Phase 3 Trial for COPD Verona Pharma NASDAQVRNA
